Contineum Therapeutics, Inc. · NASDAQ:CTNM
Contineum Therapeutics — Investor Presentation (July 2026)
32 slides from Contineum Therapeutics's investor presentation, July 2026
Slide 1: Corporate Overview
Corporate Overview JULY 2026
Slide 2: Disclaimer
Disclaimer This presentation by Contineum Therapeutics, Inc. (“Contineum”, “We” or “Our) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including
Slide 3: Investment highlights: focused execution on lead program PIPE-791
CLINICAL VALIDATION across key programs, STRONG IP for lead programs LARGE TAMs with significant unmet need in idiopathic pulmonary fibrosis (IPF), chronic pain, and major depressive disorder (MDD) MULTIPLE SHOTS-ON-GOAL with clinically-validated targets (LPAR1, M1R) Pioneering differentiated small
Slide 4: Balanced Pipeline, Clinical Validation of IPF and MDD Targets
Balanced Pipeline, Clinical Validation of IPF and MDD Targets Drug Candidate Mechanism Program Preclinical Phase 1 Phase 2 Phase 3 Worldwide Rights LPAR1 PIPE-791 Antagonist IPF LPAR1 Chronic PIPE-791 Antagonist Pain LPAR1 CTX-343(1) Antagonist Peripheral PIPE-307(2) M1R MDD (JNJ-5120) Antagonist Di
Slide 5: PIPE-791 Has Broad Therapeutic Potential
PIPE-791 Has Broad Therapeutic Potential Progressive Pulmonary Chronic Fibrosis Pain IPF (PPF) Other (Lead Fibrotic program) Diseases P I P E-7 9 1 Portfolio in a Pill A differentiated, brain penetrant LPAR1 antagonist 5
Slide 6: Pulmonary Fibrosis and Chronic Pain: structurally differentiated oral small molecule
A structurally differentiated Pulmonary Fibrosis oral, small molecule Chronic Pain Potential best-in-disease Potential to address molecule pain and quality of life High and sustained target Novel, non-opioid mechanism coverage, favorable targeting peripheral and safety and tolerability central sensi
Slide 7: Idiopathic Pulmonary Fibrosis
P I P E-7 9 1 Idiopathic Potential BEST-IN-DISEASE treatment for halting disease progression Pulmonary The ONLY low dose, 1x daily oral small Fibrosis molecule in clinical development for IPF IP COVERAGE Through 2042 7
Slide 8: PIPE-791: Potential Best-in-Disease Treatment for IPF
PIPE-791: Potential Best-in-Disease Treatment for IPF STRONG HIGHLY Clinical Validation Differentiated Profile Efficacy Clinical Validation in IPF/PPF High and sustained target engagement Safety/Tolerability 2 Phase 2 Clinical Trials Improved tolerability, no safety observations completed in IPF/PPF
Slide 9: PIPE-791: The Ideal Once Daily Backbone for Combination Treatment in IPF
PIPE-791: The Ideal Once Daily Backbone for Combination Treatment in IPF Favorable safety and tolerability High, sustained target coverage Enables potential for robust efficacy Opportunity for ≥90% receptor occupancy in combination a Foundational Molecule for Combination No GI tolerability issues, c
Slide 10: Significant Developments and Potential Derisking of Therapies for IPF
Significant Developments and Potential Derisking of Therapies for IPF 1Q26 4Q26 2027 Others PIPE-791 (IPF) ALOFT-IPF BMS ALOFT-PPF Patient dosing initiated for Estimated trial Phase 3 Readout global Phase 2 trial completion Others Estimated trial completion Multiple Phase 2 in June 2028 Readouts (IP
Slide 11: Significant Need for Differentiated Treatments in IPF
IPF +$4B Current Market(1) Current therapies have Significant Need tolerability and efficacy for Differentiated limitations Treatments No approved drugs 130K+ halt disease progression patients in the US(2) (3 FDA approved therapies) 3M patients globally(2) (1) Boehringer Ingelheim press release Marc
Slide 12: IPF: A Long and Difficult Patient Journey
IPF: A Long and Difficult Patient Journey Rare, Progressive Interstitial Lung Disease with Unknown Etiology Declining lung function ~2 years to diagnosis Unpredictable disease Variable progression treatments 60% - 80% of patients die from respiratory failure within 5 years(1) Prognosis for overall s
Slide 13: Blocking LPAR1 Inhibits Several Steps in the Fibrosis Pathway
Blocking LPAR1 Inhibits Several Steps in the Fibrosis Pathway Injury LPAR1 activation LPA-induced endothelial Increases LPA production Promotes recruitment of fibroblasts and barrier breakdown and LPAR1 expression collagen secretion leading to fibrosis and Promotes further inflammation restrictive l
Slide 14: LPAR1 Is a Clinically Validated Target in IPF and PPF
LPAR1 Is a Clinically Validated Target in IPF and PPF Two BMS Therapies Slowed the Rate of Decline in Forced Vital Capacity (FVC) in Phase 2 26-week Trials IPF IPF PPF BMS-986020 BMS-986278 BMS-986278 (n=143) wo background anti-fibrotics (n=276) w/wo background (n=123) w/wo background anti-fibrotics
Slide 15: PIPE-791: A Potent, Selective, and Sticky LPAR1 Antagonist
PIPE-791: A Potent, Selective, and “Sticky” LPAR1 Antagonist PIPE-791 Demonstrated Dose-Dependent Lung LPAR1 Very Slow On/Off with Occupancy, Well Defined Therapeutic Concentration Long Receptor Residence Time In Vivo Lung LPAR1 Occupancy In Vitro Pharmacology Properties In Vitro Profile %LPA1 Occup
Slide 16: PIPE-791 Treatment Reduced Injury-Stimulated Lung Collagen
PIPE-791 Treatment Reduced Injury-Stimulated Lung Collagen Maximal Effect Observed Using 0.3 mg/kg 0.3 mg/kg Achieves >90% with Once Daily Dosing Receptor Occupancy Total Pulmonary Collagen LPAR1 Occupancy Effect Relationship Bleomycin-induced in vivo lung fibrosis model % LPA1 Occupancy (lung) 1,50
Slide 17: Favorable Phase 1 Safety and Tolerability in Healthy Volunteers
Favorable Phase 1 Safety and Tolerability in Healthy Volunteers TRIAL SCHEMA ADVERSE EFFECTS Single-Ascending Dose Cohorts Treatment Emergent AEs Reported in ≥ 2 subjects (n=8 per cohort; 6 active, 2 placebo) AE (# of SAD SAD SAD SAD MAD MAD MAD S4: 20mg Subjects) Placebo 1 2 3 4 1 2 3 D x 1d Abdomi
Slide 18: PIPE-791 Exhibits Strong Receptor Occupancy and Target Engagement
PIPE-791 Exhibits Strong Receptor Occupancy and Target Engagement Phase 1 HV MAD Exposures(1) 10 mg MAD, D14 3 mg MAD, D7 Powerful PIPE-791 (ng/mL) differentiation 1 mg dose achieves 90% RO* >90% receptor PET Trial 1 mg MAD, D7 occupancy with 1x daily dosing 50% RO* Time Since Dosing (in hours) *168
Slide 19: PIPE-791 Clinical Development Plans in IPF
PIPE-791 Clinical Development Plans in IPF Phase 2 Global, Double-Blind, Placebo Controlled, Multi-Center Trial(1) Primary Outcome Measures Absolute change in forced vital capacity (FVC) from Approximately 324 subjects baseline through week 26 1:1:1 Randomization Secondary Outcome Measures Placebo (
Slide 20: Chronic Pain
P I P E-7 9 1 Opportunity to address PAIN AND Chronic QUALITY OF LIFE Pain A potential DIFFERENTIATED non- opioid treatment for patients DERISKS the safety and tolerability profile of the IPF program 20
Slide 21: LPA is an important factor in chronic pain
LPA is an important factor in chronic pain… …and the only way to get to it is with a brain penetrant molecule P I P E-7 9 1 The ONLY Brain Penetrant LPAR1 Antagonist Addresses Non Non peripheral opioid sedating and central sensitization 21
Slide 22: Novel Approaches Are Needed to Reduce Chronic Pain
Novel Approaches Are Needed to Reduce Chronic Pain OSTEOARTHRITIS (OA) LOW BACK PAIN (LBP) 33M(1) Patients in the U.S. 45M(3) 15% - 25%(2) % of Patients with Neuropathic Pain 20% - 55%(4) • Current treatments considered suboptimal and are limited for patients with OA and LBP • OA and LBP are both cl
Slide 23: PIPE-791 LPA Levels Increase Following Nerve Injury
PIPE-791 LPA Levels Increase Following Nerve Injury (Correlates with pain intensity and disease severity) Potential to Modify Maladaptive Changes Associated with Pain Central sensitization PIPE-791 Central Action Peripheral sensitization blocks Inflammatory microglia here within the spinal cord LPA1
Slide 24: PIPE-791 Phase 1B Chronic Pain Clinical Trial Schema
PIPE-791 Phase 1B Chronic Pain Clinical Trial Schema(1) Randomized, Double-Blind, • 43 patients - 23 with chronic osteoarthritis pain (COAP), 20 with chronic lower back pain (CLBP) Placebo-Controlled, • Primary endpoint for safety & tolerability 4-week Crossover Trial • Multiple exploratory endpoint
Slide 25: Favorable Safety and Tolerability, Consistent Improvement Across Multiple Pain Measures
Favorable Safety and Tolerability, Consistent Improvement Across Multiple Pain Measures SAFETY & TOLERABILITY • Favorable profile at the 1x daily 10mg oral dose — the largest patient population and longest treatment duration studied to date at highest MAD dose PIPE-791 • Most treatment-emergent adve
Slide 26: Favorable Safety & Tolerability Profile in the Phase 1B Chronic Pain Trial
PIPE-791 Demonstrated a Favorable Safety & Tolerability Profile in the Phase 1B Chronic Pain Trial • Most common TEAEs were headache (n=3) and fatigue (n=2) • NO clinically meaningful changes in laboratory values and ECG findings across treatment groups • NO clinically meaningful changes in vital si
Slide 27: Portfolio in a Pill
P I P E-7 9 1 STRUCTURALLY DIFFERENTIATED Portfolio oral small molecule in a Pill THE ONLY brain penetrant LPA1 antagonist UNLOCKS a differentiated opportunity 27
Slide 28: Admilparant (BMS-986278) Multiple Potential Limitations
DESIGN CNS Penetrant No (Peripheral only) Admilparant IPF (BMS-986278) Target Coverage Suboptimal Slow On/Off No Multiple Potential Limitations Hypotension Risk Yes Dose Titration Required in previous studies Dosing 2x per day CHRONIC PAIN Pain Indication Pursued No Pain Mechanism Coverage Periphera
Slide 29: PIPE-791 Highly Differentiated
DESIGN CNS Penetrant Yes (Confirmed in vivo) PIPE-7 9 1 IPF Highly Target Coverage High and sustained Differentiated Slow On/Off Yes Hypotension Risk None observed Dose Titration No Dosing 1x per day CHRONIC PAIN Pain Indication Pursued Yes Pain Mechanism Coverage Peripheral and central 29
Slide 30: Depression
P I P E-3 07 Depression A selective M1R antagonist with a clinically validated mechanism $1 billion partnering agreement 30
Slide 31: PIPE-307 (JNJ-5120) Highlights
PIPE-307 (JNJ-5120) Highlights DEAL TERMS MARKET OPPORTUNITY $50M $25M >$1B Upfront cash Equity investment Total milestones Royalties Low-double digit → high-teens % of net sales 280M (1) Existing therapies offer only partial response – significant (if approved) Patients globally unmet need remains
Slide 32: Focused Execution of PIPE-791 Lead Program
Highly differentiated Focused Execution of PIPE-791 Lead Program Clinical validation PORTFOLIO IN A PILL Large TAMs Disciplined capital allocation Cash runway through mid-2029 32
Contineum Therapeutics — Investor Presentation (July 2026) on 6ix